126
|
Joshi P, Saxena A, Kaul U, Mansoor AH. Catecholaminergic polymorphic ventricular tachycardia with associated sinus node dysfunction. Indian Heart J 2010; 62:84-86. [PMID: 21180045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
Abstract
An 11-year-old Nepalese male child presented with history of recurrent abrupt episodes of syncope for the last one year. There was no family history of sudden death at a young age in his family. ECG at base-line revealed an isorhythmic AV dissociation with a heart rate of 50 bpm and a normal QTc. Echocardiography of the heart was normal. His 24 hour holter study revealed frequent VPC's and episodes of polymorphic ventricular tachycardia. Exercise stress test provoked a polymorphic VT. On EP study, sinus node recovery time (SNRT) was prolonged and ventricular tachycardia (VT) was induced on Isoproterenol infusion. He was treated with a permanent pacemaker and beta-blocker.
Collapse
|
127
|
Hussain A, Kaul U. Recent landmark trials in cardiology. JOURNAL OF THE INDIAN MEDICAL ASSOCIATION 2009; 107:706-714. [PMID: 20469745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
|
128
|
Mansoor AH, Kaul U. Pre-hospital thrombolysis. Indian Heart J 2009; 61:433-436. [PMID: 20635757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023] Open
|
129
|
Mansoor AH, Aggarwal P, Bhardwaj S, Tandon V, Kaul U. Coronary vasospasm presenting as Prinzmetals angina and life threatening Brady-arrhythmia independently at different times. Indian Heart J 2009; 61:389-391. [PMID: 20635748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023] Open
Abstract
A 65-years-old female presented with features suggesting acute coronary syndrome, initially as non STEMI and later as classical Prinzmetal's angina. While being treated she also had recurrent episodes of dizziness and cardiac arrest due to complete heart block and asystole. These episodes occurred while on nitroglycerine infusion and were not accompanied by chest pain or ST-T segment changes. Coronary angiography revealed evidence of reversible multi-vessel coronary spasm. Electrophysiological studies were normal. She was treated with nitrates and calcium blockers and a permanent pacemaker implantation.
Collapse
|
130
|
Bhatia V, Arora P, Parida AK, Mittal A, Pandey AK, Kaul U. Air travel and pulmonary embolism: "economy class syndrome". THE JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA 2009; 57:412-414. [PMID: 19634292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Air travel is implicated as a predisposing factor for thromboembolism, which at times can have catastrophic consequences. We present three cases who developed deep vein thrombosis (DVT) and subsequent pulmonary thromboembolism (PTE) after transatlantic air travel.
Collapse
|
131
|
Chan C, Zambahari R, Kaul U, Lau CP, Whitworth H, Cohen S, Buchbinder M. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study. Catheter Cardiovasc Interv 2009; 72:591-600. [PMID: 18949772 DOI: 10.1002/ccd.21719] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
OBJECTIVE To compare the effects of sirolimus-eluting (SES) versus bare metal stents (BMS) on 6-month in-stent late luminal loss (LLL) and 1-year major adverse cardiac events (MACE) in diabetics undergoing percutaneous coronary interventions. BACKGROUND In studies of unselected patients, coronary restenosis rates have been lower with SES than with BMS. Comparisons of SES versus BMS in diabetics with more than one stenosis or more than one vessel disease are few. METHODS This open-label trial randomly assigned 200 diabetics with de novo coronary artery stenoses to receive up to three SES versus BMS in a 2:1 ratio. The patients underwent repeat coronary angiography at 6 months after the index procedure and were followed-up for 1 year. The primary study endpoint was in-stent LLL at 6 months. RESULTS Between August 2002 and May 2004, 83 patients (mean age = 60 years) with 128 lesions (mean = 1.5 per patient) were enrolled at four U.S. and seven Asian medical centers. Enrollment was terminated early by the Safety Monitoring Board because of a statistically significant difference in rates of clinical endpoints. The mean in-stent LLL at 6 months was 0.23 mm in SES versus 1.10 mm in BMS recipients (P < 0.001). At 12 months, 8 patients (15%) assigned to SES had experienced MACE versus 12 patients (41%) assigned to BMS (P = 0.006). CONCLUSIONS In diabetics, the mean 6-month in-stent LLL was significantly smaller, and 12-month MACE rate significantly lower, after myocardial revascularization with SES than with BMS.
Collapse
|
132
|
Kaul U, Bhatia V. Choice of DES: is there a difference? HEART ASIA 2009; 1:11-5. [PMID: 27325919 DOI: 10.1136/ha.2008.000224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Accepted: 12/22/2008] [Indexed: 11/04/2022]
Abstract
Restenosis after percutaneous coronary interventions has been a major limitation of this otherwise very well-accepted method of coronary revascularisation. Coronary stents work by scaffolding the intimal flaps and preventing elastic recoil, which was a major problem after balloon angioplasty. The neointimal growth response to stenting contributes significantly to the restenotic process. Randomised studies comparing coronary artery bypass surgery with coronary stenting especially in multivessel disease clearly highlighted this problem. The problem has been greater in magnitude in special subgroups: diabetics, patients with small vessels (≤2.5 mm in diameter), long segments of disease (≥20 mm in length), etc. These limitations of Bare metal stents have been addressed by drug-eluting stents (DESs). Third-generation stents with bioabsorbable polymers like the Biolimus releasing Biomatrix stent have already become available in Europe and parts of Asia. A longer follow-up will prove their long-term safety vis-à-vis first-generation DES. The polymer-free stent with capability of using more than one drug, though very attractive, needs larger multicentric studies before gaining wider acceptance. The fully bioabsorbable stent is yet another promising concept. The feasibility has already been demonstrated, and finer refinements are under way. The future of newer DES thus is very promising, and most of the issues related to first-generation DES are at the threshold of being solved.
Collapse
|
133
|
Kumar V, Ghosh B, Kaul U, Thakar M, Goel N. Posterior polar cataract surgery: a posterior segment approach. Eye (Lond) 2008; 23:1879; author reply 1879. [PMID: 18989342 DOI: 10.1038/eye.2008.347] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
134
|
Bhatia V, Arora P, Parida AK, Singh G, Kaul U. Air travel and pulmonary embolism: "economy class syndrome". Indian Heart J 2008; 60:608-611. [PMID: 19276509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
Air travel is implicated as a predisposing factor for thromboembolism, which at times can have catastrophic consequences. We present 3 cases who developed deep vein thrombosis (DVT) and subsequent pulmonary thromboembolism (PTE) after transatlantic air travel. The relevant literature is discussed.
Collapse
|
135
|
Arora P, Bhatia V, Parida AK, Kaul U. Myocardial Bridge in association with fixed atherosclerotic lesions treated with drug-eluting stents: a follow-up report with quantitative coronary analysis. Indian Heart J 2008; 60:594-596. [PMID: 19276504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
Stenting of muscle bridge is still a controversial issue with concerns regarding high restenosis rates, plaque prolapse and stent fracture. We report a case with significant atherosclerotic disease of right coronary artery and left anterior descending artery associated with a muscle bridge, proximal to the diseased segment which became more prominent after stenting the fixed lesion. This was managed by implanting another drug eluting stent, covering the bridge. Angiographic follow-up at 9 months revealed no difference in quantitative coronary angiography parameters in the stented segment of the bridge, as compared to other stented segments.
Collapse
|
136
|
Kaul U, Bhatia V, Ghose T, Gupta R, Kachru R, Singh G. Angiographic follow-up of genous bioengineered stent in acute myocardial infarction (GENAMI)-a pilot study. Indian Heart J 2008; 60:532-535. [PMID: 19276491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
OBJECTIVE GENAMI, an angiographic follow-up study was undertaken to evaluate the safety and efficacy of a new generation endothelial progenitor cell (EPC) capture stent, GENOUS during primary angioplasty for ST-elevation myocardial infarction (MI). METHODS Eleven consecutive patients with acute ST-elevation MI underwent primary percutaneous coronary intervention (PCI) using a bio-engineered GENOUS EPC stent. RESULTS Procedural success was 100%. Ten patients who survived underwent a follow-up angiography at 8 months. There was no instance of stent thrombosis during the follow-up period up to 12 months. The quantitative angiographic (quantitative coronary analysis [QCA]) follow-up data showed a late loss at 8 months of 0.97 +/- 0.94 mm and the late loss index was 44.35 +/- 40.47% with angiographic restenosis seen in 5 of 10 patients (50%). One of these patients with provocable ischemia underwent repeat PCI. CONCLUSIONS The QCA data of this study shows a high late loss with frequent angiographic restenosis during follow-up with this stent during primary PCI for acute STEMI. This observation, with important clinical implications, needs to be confirmed in larger studies.
Collapse
|
137
|
Bhatia V, Mittal A, Parida AK, Talwar R, Kaul U. Amlodipine induced gingival hyperplasia: A rare entity. Int J Cardiol 2007; 122:e23-4. [PMID: 17275935 DOI: 10.1016/j.ijcard.2006.11.066] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2006] [Accepted: 11/02/2006] [Indexed: 12/13/2022]
Abstract
Drug induced gingival hyperplasia is an uncommon entity. Anticonvulsants, immunosuppressants and calcium channel blockers are often implicated. We report a case of a 52-year old male who developed amlodipine induced gingival hyperplasia. The etiology and treatment modalities are discussed.
Collapse
|
138
|
Bhatia V, Sapra R, Mittal A, Pandey A, Gupta R, Kachru R, Arora P, Parida A, Singh G, Kaul U. Mobile intracardiac thrombi: clinical scenarios and management strategies. Indian Heart J 2007; 59:284-287. [PMID: 19124942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
139
|
Bhatia V, Parida AK, Pandey AK, Kaul U. 12 lead ECG in the detection of left main coronary artery occlusion during acute coronary syndromes. Int J Cardiol 2007; 116:e83-4. [PMID: 17126932 DOI: 10.1016/j.ijcard.2006.08.103] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2006] [Accepted: 08/12/2006] [Indexed: 11/27/2022]
Abstract
A careful evaluation of the 12 Lead surface ECG may help detect Left Main Coronary artery (LMCA) occlusion. Since LMCA occlusion can cause rapid hemodynamic and electrical deterioration, early identification may help the treating team to plan out timely revascularization. We describe a 61 years old male who presented with acute anterior wall myocardial infarction and where LMCA occlusion was suspected on the basis of surface ECG. The diagnostic criteria available are discussed.
Collapse
|
140
|
Bhatia V, Kaul U. Common errors in ECG diagnosis of coronary artery disease. THE JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA 2007; 55 Suppl:7-9. [PMID: 18376490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
A variety of clinical conditions not associated with ischemic heart disease can have ECG features mimicking those of ischemic etiology. Some of these entities are: ventricular hypertrophy, intraventricular conduction defects, pre-excitation syndrome, pericarditis, electrolyte disturbances, etc. This can lead to erroneous diagnosis and uncalled for hazardous treatment. A careful comprehensive evaluation with in depth analysis of the ECG can overcome such errors. We have reviewed some of these conditions and elaborated upon the differentiating features.
Collapse
|
141
|
Kaul U, Gupta RK, Mathur A, Dani S, Sapra R, Nayak PR, Lansky A, Cristea E, Carlier S, Gambone L, Litvack F. Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I). Indian Heart J 2007; 59:165-172. [PMID: 19122251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
BACKGROUND The CoStar stent is a novel cobalt chromium stent designed specifically for drug delivery. The COSTAR I trial represents the first-in-man study of the CoStar Paclitaxel-Eluting Coronary Stent System evaluating three dose release formulations of paclitaxel in a bioresorbable polymer matrix in the treatment of de novo coronary lesions. METHODS The COSTAR I Trial was a prospective, multi-center registry enrolling 87 patients in four Indian centers for treatment of up to two de novo lesions = 25 mm in length in a reference vessel 2.5-3.5 mm in diameter. Three dose release formulations were studied: 30 microg eluted over 10 days bidirectionally (Group 1, n =10), 10 microg eluted over 30 days abluminally (Group 2, n=40) and 3 microg eluted over 30 days abluminally (Group 3, n = 37). RESULTS Demographics and lesion characteristics were similar between the groups and treatment in all three groups included small caliber vessels (RVD 2.45 +/- 0.30 - 2.57 +/- 0.36 mm). The primary endpoint of in-stent late loss at four months was lowest in Group 2 (0.43 +/- 0.43 mm) compared to Group 1 and Group 3 (0.51 +/- 7 mn; 0.74 mm and 1.07 +/- 0.65 mm respectively). In-segment late loss followed similar trends, being lowest in Group 2 (0.24 +/- 0.39 mm) compared to Groups 1 and 3 (0.52 +/- 0.66 mm and 0.76 +/- 0.57 mm respectively). Group 2 demonstrated better angiographic out-comes at 12 months with in-stent late loss of 0.55 +/- 0.38 mm when compared to Groups 1 and 3 (0.90 +/- 0.76 mm and 0.74 +/- 0.55 mm respectively). Cumulative binary restenosis rates at twelve months were 1.9%, 35.7% and 39.1% in Groups 2, 1 and 3 respectively. Clinical outcomes trended similarly with cumulative MACE rates at twelve months being lowest at 7.5% in Group 2 as compared to 20% in Group 1 and 21.6% in Group 3 respectively. CONCLUSIONS In this first-in-man feasibility trial, angiographic and clinical results seen with the extended release formulation at a higher dose (10 microg/30 days) demonstrate the feasibility of the CoStar stent platform in the treatment of native coronary lesions. It also demonstrates the importance of drug dose and release kinetics.
Collapse
|
142
|
Bhatia V, Kaul U. Diverse DES usage: Indian perspective and data. Indian Heart J 2007; 59:B9-B15. [PMID: 19153442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
143
|
Bhatia V, Kachru R, Kaul U. Very late stent thrombosis after implantation of drug eluting stent. THE JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA 2006; 54:879-80. [PMID: 17249257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
A case of late stent occlusion of a Sirolimus eluting Cypher stent (Cordis, Johnson and Johnson) presenting as acute ST elevation myocardial infarction 22 months after deployment is reported. The possible mechanisms are discussed.
Collapse
|
144
|
Kaul U, Iyengar SS, Kerkar PG, Mohan JC, Kumar S. Consensus development guidelines for the role of LMWHs in the management of unstable coronary artery disease: an Indian perspective. THE JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA 2006; 54 Suppl:6-26. [PMID: 17357442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
|
145
|
Abizaid A, Chan C, Lim YT, Kaul U, Sinha N, Patel T, Tan HC, Lopez-Cuellar J, Gaxiola E, Ramesh S, Rodriguez A, Russell ME. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM Registry). Am J Cardiol 2006; 98:1028-32. [PMID: 17027565 DOI: 10.1016/j.amjcard.2006.05.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2006] [Revised: 05/11/2006] [Accepted: 05/11/2006] [Indexed: 10/24/2022]
Abstract
The WISDOM Registry tracked clinical outcomes in patients receiving a slow-release, polymer-based, paclitaxel-eluting stent during the transition from randomized trials to commercial use in everyday interventional cardiology practice. Although randomized trials of drug-eluting stents have demonstrated the safety and effectiveness of these devices in less complicated, de novo lesions, observation of long-term clinical outcomes is required to monitor safety as use of this revolutionary technology expands to broader patient populations. In total, 778 patients were enrolled at 22 sites in 9 countries where the TAXUS paclitaxel-eluting stent first received market approval. Patients with de novo or restenotic coronary lesions eligible for stenting were enrolled. Clinical follow-up was conducted by telephone at 3, 6, 9, and 12 months after the procedure to capture reported stent thrombosis and major cardiac events (death, myocardial infarction, and reintervention on the target lesion). Clinical follow-up at 12 months was completed for 92% of patients. The 12-month rate of physician-reported major cardiac events was 5.2%, with a target lesion reintervention rate of 2.0%. The low overall stent thrombosis rate of 0.6% included no stent thromboses >30 days after the index procedure. Low target lesion reintervention rates were also observed in the high-risk subgroups: patients with diabetes (4.0%), vessels <2.5 mm (2.5%), lesions >20 mm (3.6%), and multiple stents in a lesion (1.4%). In conclusion, the paclitaxel-eluting TAXUS slow-release stent exhibits long-term safety and efficacy in uncomplicated and higher risk patients and lesions seen in everyday clinical practice.
Collapse
|
146
|
Gupta RK, Sapra R, Kaul U. Early aneurysm formation after drug-eluting stent implantation: an unusual life-threatening complication. THE JOURNAL OF INVASIVE CARDIOLOGY 2006; 18:E140-2. [PMID: 16723749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
Coronary aneurysm after stent implantation is a rare complication. Coronary aneurysms have been reported after drug-eluting stent implantation, but there has been no clear elucidation of time course, mechanism and therapeutic implications. We report two patients who developed coronary aneurysms within two weeks of the procedure and required surgical intervention to treat the complication. The possible putative mechanisms are discussed.
Collapse
|
147
|
Sapra RR, Gupta R, Kachru R, Kaul U. Re: renal artery stent placement: a simple technique to intubate the renal artery in difficult situations. J Vasc Interv Radiol 2006; 17:186-7. [PMID: 16415154 DOI: 10.1097/01.rvi.0000188751.46351.a7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
148
|
Kaul U. Safety issues with drug-eluting stents-is caution warranted? Indian Heart J 2006; 58:5-6. [PMID: 18984922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
149
|
Bhatia V, Kachru R, Sapra R, Gupta RK, Nair M, Mittal A, Kumar M, Mahant T, Kaul U. Diffuse unilateral pulmonary arteriovenous fistulae-a rare anomaly. Indian Heart J 2006; 58:65-67. [PMID: 18984936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
Diffuse pulmonary arteriovenous fistulae are rare, more so when unilateral. This article describes a 12-year-old boy with diffuse right-sided pulmonary arteriovenous fistula in whom prior percutaneous transcatheter coil occlusion has been attempted without success.The patient was subjected to ligation and transection of the right pulmonary artery and he is presently doing well.
Collapse
|
150
|
Chen WH, Kaul U, Leung SK, Lau YK, Tan HC, Leung AWS, Lee MKY, Li SK, Ng W, Lee PY, Lam KF, Tse HF, Lau CP. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. THE JOURNAL OF INVASIVE CARDIOLOGY 2005; 17:534-8. [PMID: 16204748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
OBJECTIVES Coronary stenting is associated with a high incidence of restenosis in patients with diabetes mellitus. Recent data suggest that diabetic patients treated with abciximab have a lower rate of target vessel revascularization (TVR). We sought to investigate whether abciximab can reduce in-stent restenosis after coronary stenting in diabetic patients. METHODS In this prospective double-blind trial, we randomly assigned 254 patients with type 2 diabetes mellitus undergoing nonurgent coronary stenting to receive abciximab with an initial heparin bolus of 50 U/kg (n = 128) or placebo with an initial heparin bolus of 70 U/kg (n = 126). All patients received aspirin and clopidogrel before the procedure. The primary endpoint was angiographic restenosis by quantitative coronary angiography at 6 months. The secondary endpoint was death, myocardial infarction (MI), or target lesion revascularization (TLR) at 6 months. RESULTS The clinical, angiographic, and procedural characteristics were matched between the 2 groups. Angiographic follow-up was completed in 226 patients (90%). Angiographic restenosis occurred in 29.1% of the abciximab group, and 24% of the placebo group (p = 0.30). The rates of the secondary endpoint were similar between the 2 groups (23.4% in the abciximab group versus 22.2% in the placebo group; p = 0.88). TLR was performed on 36 (18.4%) lesions in 29 (23.4%) patients of the abciximab group, and 26 (13.6%) lesions in 23 (18.3%) patients of the placebo groups, respectively (p = 0.21 and 0.35, respectively). CONCLUSIONS Abciximab does not reduce angiographic restenosis or TLR in type 2 diabetic patients undergoing nonurgent coronary stenting.
Collapse
|